Preventing respiratory syncytial virus in infants
How safe and effective are monoclonal antibodies in preventing respiratory syncytial virus (RSV) in infants? In infants at high risk (born prematurely or with congenital heart or lung conditions), palivizumab (4 to 5 monthly doses during RSV season) reduces RSV hospitalization (4.4% vs 9.8%
Authors
- Samantha S. Moe
- Michael R. Kolber (ORCID: https://orcid.org/0000-0001-7490-4633)
- Sam Wong (ORCID: https://orcid.org/0000-0002-2589-3891)
Institutions
- University of Alberta (CA)
- University of Alberta Hospital (CA)
- College of Family Physicians of Canada (CA)
Publication Details
- Journal
- Canadian Family Physician
- Published
- 2024-10-01
- DOI
- https://doi.org/10.46747/cfp.7010e155
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00